Advanced Search
WU Youjun, DU Xiaohui. Role of Adenosine 2a Receptor in Promoting Immune-suppressive Status in Tumor Microenvironment[J]. Cancer Research on Prevention and Treatment, 2017, 44(6): 433-436. DOI: 10.3971/j.issn.1000-8578.2017.16.1400
Citation: WU Youjun, DU Xiaohui. Role of Adenosine 2a Receptor in Promoting Immune-suppressive Status in Tumor Microenvironment[J]. Cancer Research on Prevention and Treatment, 2017, 44(6): 433-436. DOI: 10.3971/j.issn.1000-8578.2017.16.1400

Role of Adenosine 2a Receptor in Promoting Immune-suppressive Status in Tumor Microenvironment

More Information
  • Received Date: November 16, 2016
  • Revised Date: February 17, 2017
  • Available Online: January 12, 2024
  • Adenosine 2a receptor (A2aR) is a type of G-protein coupled receptor widely existing on the surface of various immune cells, and plays important role in the regulation of host immune functions through its binding with adenosine(ADO). Here we summarize the significance of A2aR in promoting the immune-suppressive status in tumor microenvironment, and provide evidence for the clinical application of treatment interfering with A2aR.

  • [1]
    Zimmermann H. Extracellular ATP and other nucleotides-ubiquitous triggers of intercellular messenger release[J]. Purinergic Signal, 2016, 12(1): 25-57. doi: 10.1007/s11302-015-9483-2
    [2]
    Cekic C, Linden J. Purinergic regulation of the immune system[J]. Nat Rev Immunol, 2016, 16(3): 177-92. doi: 10.1038/nri.2016.4
    [3]
    Fredholm BB, IJzerman AP, Jacobson KA, et al. International union of basic and clinical pharmacology. LXXXI. nomenclature and classification of adenosine receptors-an update[J]. Pharmacol Rev, 2011, 63(1): 1-34. doi: 10.1124/pr.110.003285
    [4]
    Linnemann C, Schildberg FA, Schurich A, et al. Adenosine regulates CD8 T cell priming by inhibition of membrane-proximal T cell receptor signalling[J]. Immunology, 2009, 128(1 Suppl): e728-737. https://www.researchgate.net/publication/51438279_Adenosine_regulates_CD8_T-cell_priming_by_inhibition_of_membrane-proximal_T-cell_receptor_signaling
    [5]
    Su Y, Jackson EK, Gorelik E. Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes[J]. Cancer Immunol Immunother, 2011, 60(1): 111-22. doi: 10.1007/s00262-010-0924-z
    [6]
    Chimote AA, Hajdu P, Kucher V, et al. Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells[J]. J Immunol, 2013, 191(12): 6273-80. doi: 10.4049/jimmunol.1300702
    [7]
    Elson G, Eisenberg M, Garg C, et al. Induction of murine adenosine A(2A) receptor expression by LPS: analysis of the 5' upstream promoter[J]. Genes Immun, 2013, 14(3): 147-53. doi: 10.1038/gene.2012.60
    [8]
    He X, Hu JL, Li J, et al. A feedback loop in PPARγ-adenosine A2A receptor signaling inhibits inflammation and attenuates lung damages in a mouse model of LPS-induced acute lung injury[J]. Cell Signal, 2013, 25(9): 1913-23. doi: 10.1016/j.cellsig.2013.05.024
    [9]
    Hatfield SM, Kjaergaard J, Lukashev D, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation[J]. Sci Transl Med, 2015, 7(277): 277ra30. doi: 10.1126/scitranslmed.aaa1260
    [10]
    Cekic C, Day YJ, Sag D, et al. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment[J]. Cancer Res, 2014, 74(24): 7250-9. doi: 10.1158/0008-5472.CAN-13-3583
    [11]
    Ferrante CJ, Pinhal-Enfield G, Elson G, et al. The adenosine-dependent angiogenic switch of macrophages to an M2 like phenotype is independent of interleukin 4 receptor α (IL 4Rα) signaling[J]. Inflammation, 2013, 36(4): 921-31. doi: 10.1007/s10753-013-9621-3
    [12]
    Li L, Huang L, Ye H, et al. Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury[J]. J Clin Invest, 2012, 122(11): 3931-42. doi: 10.1172/JCI63170
    [13]
    Liu C, Shang Q, Bai Y, et al. Adenosine A2A receptor, a potential valuable target for controlling reoxygenated DCs-triggered inflammation[J]. Mol Immunol, 2015, 63(2): 559-65. doi: 10.1016/j.molimm.2014.10.012
    [14]
    Sitkovsky MV, Hatfield S, Abbott R, et al. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists[J]. Cancer Immunol Res, 2014, 2(7): 598-605. doi: 10.1158/2326-6066.CIR-14-0075
    [15]
    Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells[J]. Front Immunol, 2014, 5: 304. https://www.researchgate.net/publication/264393953_Extracellular_Adenosine-Mediated_Modulation_of_Regulatory_T_Cells
    [16]
    Smyth LA, Ratnasothy K, Tsang JY, et al. CD73 expression on extracellular vesicles derived from CD4+CD25+Foxp3+ T cells contributes to their regulatory function[J]. Eur J Immunol, 2013, 43(9): 2430-40. doi: 10.1002/eji.201242909
    [17]
    Leone RD, Lo YC, Powell JD. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy[J]. Comput Struct Biotechnol J, 2015, 13: 265-72. doi: 10.1016/j.csbj.2015.03.008
    [18]
    Ohta A. A metabolic immune checkpoint: adenosine in tumor microenvironment[J]. Front Immunol, 2016, 7: 109. https://www.researchgate.net/publication/299474542_A_Metabolic_Immune_Checkpoint_Adenosine_in_Tumor_Microenvironment
    [19]
    Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors[J]. Proc Natl Acad Sci U S A, 2013, 110(36): 14711-6. doi: 10.1073/pnas.1308209110
    [20]
    Young A, Ngiow SF, Barkauskas DS, et al. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses[J]. Cancer Cell, 2016, 30(3): 391-403. doi: 10.1016/j.ccell.2016.06.025
    [21]
    Eini H, Frishman V, Yulzari R, et al. Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A 2A receptor[J]. Biochem Pharmacol, 2015, 98(1): 110-8. doi: 10.1016/j.bcp.2015.08.092
    [22]
    Waickman AT, Alme A, Senaldi L, et al. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor[J]. Cancer Immunol Immunother, 2012, 61(6): 917-26. doi: 10.1007/s00262-011-1155-7
    [23]
    Allard D, Turcotte M, Stagg J. Targeting A2 adenosine receptors in cancer[J]. Immunol Cell Biol, 2017, 95(4): 333-9. doi: 10.1038/icb.2017.8
    [24]
    Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease[J]. Expert Opin Pharmacother, 2012, 13(1): 111-4. doi: 10.1517/14656566.2012.643869
    [25]
    Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial[J]. Lancet Neurol, 2014, 13(8): 767-76. doi: 10.1016/S1474-4422(14)70148-6
  • Related Articles

    [1]XIA Lin, YU Guozheng, TANG Jing. Diagnostic Value of Circular RNAs for Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 864-870. DOI: 10.3971/j.issn.1000-8578.2021.21.0069
    [2]LIANG Tong, LIU Huajie, DA Mingxu. Metabolic Syndrome and Risk of Gastric Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 268-273. DOI: 10.3971/j.issn.1000-8578.2021.20.0957
    [3]SHAO Lihua, ZHANG Qiuning, LUO Hongtao, YANG Zhen, LIU Ruifeng, TIAN Jinhui, LI Zheng, WANG Xiaohu, YANG Kehu. Carbonions and Proton Therapy for Hepatocellular Carcinoma: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 358-366. DOI: 10.3971/j.issn.1000-8578.2020.19.1158
    [4]KUANG Yuhui, CHEN Xinju, XU Fangbiao. Meta-analysis of Efficacy and Safety of Jinlong Capsule Combined with Chemoradiotherapy on Liver Metastases[J]. Cancer Research on Prevention and Treatment, 2020, 47(1): 63-69. DOI: 10.3971/j.issn.1000-8578.2020.19.0619
    [5]RAO Xionghui, LUO Hongliang, HUANG Jun, ZHU Zhengming. Prognostic and Clinicopathological Significance of PD-L1 Expression for Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 1013-1021. DOI: 10.3971/j.issn.1000-8578.2019.19.0363
    [6]JIAN Yaowen, XIONG Wenjing, LIU Ye, LIU Yang, YANG Huixian, RANG Weiqing. A Meta-analysis on Relationship of Dietary Factors with Liver Cancer in Chinese Population[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 493-500. DOI: 10.3971/j.issn.1000-8578.2017.16.1465
    [7]TAN Yi, LIU Yan, SONG Yuwei, CHEN Qiufang, TAN Guoqiang, GUI Xiujuan, LIN Shaoqiang. Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 783-788. DOI: 10.3971/j.issn.1000-8578.2016.09.011
    [8]LV Peng, HU Zhi-jian. A Meta Analysis on Relationship between Alcohol Dehydrogenase2 Polymorphisms and Risk of Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 579-583. DOI: 10.3971/j.issn.1000-8578.2011.05.027
    [9]QIU Yue-feng, CAI Lin. Meta-analysis on Relationship between Body Mass Index and Lung Cancer Risk[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 218-222. DOI: 10.3971/j.issn.1000-8578.2010.02.025
    [10]ZHONG Qiu-an, QIU Xiao-qiang, JIANG Jun-jun, DENG Ying-ying, YU Hong-ping. Association between Diabetes Mellitus and Hepatocellular Carcinoma: A Meta- analysis of Cohort Study[J]. Cancer Research on Prevention and Treatment, 2010, 37(01): 97-100. DOI: 10.3971/j.issn.1000-8578.2010.01.027

Catalog

    Article views (1990) PDF downloads (1143) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return